Author(s):
G. Nagarajaperumal, Renjith J, Sarif Niroush Konari, Ashif Anjukandan, Noushad KT, Ibrahim Afsal VT, Dhanya. P, Anjana John
Email(s):
tgnp.1979@gmail.com
DOI:
10.52711/0974-360X.2025.00657 
Address:
G. Nagarajaperumal1*, Renjith J2, Sarif Niroush Konari3, Ashif Anjukandan4, Noushad KT5, Ibrahim Afsal VT6, Dhanya. P7, Anjana John8
1Professor and Head, Department of Pharmacology, JDT Islam College of Pharmacy Vellimadukunnu, Kozhikode, Kerala 673012.
2Professor and Head, Department of Pharmacy Practice, JDT Islam College of Pharmacy Vellimadukunnu, Kozhikode, Kerala 673012.
3Professor and Head, Department of Pharmaceutical Analysis, JDT Islam College of Pharmacy Vellimadukunnu, Kozhikode, Kerala 673012.
4Associate Professor Department of Pharmaceutics, JDT Islam College of Pharmacy Vellimadukunnu, Kozhikode, Kerala 673012.
5Associate Professor Department of Pharmaceutical Chemistry, JDT Islam College of Pharmacy Vellimadukunnu, Kozhikode, Kerala 673012.
6Professor and Vice Principal, Department of Pharmaceutics, JDT Islam College of Pharmacy Vellimadukunnu, Kozhikode, Kerala 673012.
7Assistant Professor Department of Pharmacology, JDT Islam College of Pharmacy Vellimad
Published In:
Volume - 18,
Issue - 9,
Year - 2025
ABSTRACT:
Pharmacovigilance (PV) is a crucial field that ensures patient safety by monitoring the use of drugs, whether taken orally or administered in another way. In Kerala, PV is still in its early stages, and much remains to be done and learned to achieve the safe implementation of PV activities. Solitary challenges Kerala remains under-reporting of ADRs. The increasing numbers of hospitalizations were Kerala due to drug-related ADR varieties problematic to identify the exact cause, especially when patients are preserving several medications instantaneously. Trendy this assessment sightsee various assessment scales used for ADR evaluation and identify the causative agents.
Cite this article:
G. Nagarajaperumal, Renjith J, Sarif Niroush Konari, Ashif Anjukandan, Noushad KT, Ibrahim Afsal VT, Dhanya. P, Anjana John. Navigating Drug Safety Efficacy at Hospitals in Kerala: A Review of Pharmacovigilance Practices Critical Global Strategy for Drug Safety Monitoring. Research Journal of Pharmacy and Technology. 2025;18(9):4578-2. doi: 10.52711/0974-360X.2025.00657
Cite(Electronic):
G. Nagarajaperumal, Renjith J, Sarif Niroush Konari, Ashif Anjukandan, Noushad KT, Ibrahim Afsal VT, Dhanya. P, Anjana John. Navigating Drug Safety Efficacy at Hospitals in Kerala: A Review of Pharmacovigilance Practices Critical Global Strategy for Drug Safety Monitoring. Research Journal of Pharmacy and Technology. 2025;18(9):4578-2. doi: 10.52711/0974-360X.2025.00657 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-9-77
REFERENCES:
1. Pipasha B, Biswas AK. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol. 2007; 39(3): 124-8. DOI: 10.4103/0253-7613.33432
2. WHO. Pharmacovigilance: Ensuring the Safe Use of Medicines. Geneva: WHO; 2004. DOI: Not available (WHO publications generally do not have DOIs).
3. WHO. Policy Perspectives on Medicines. Geneva: WHO; 2004. DOI: Not available (WHO publications generally do not have DOIs).
4. Skalli S, Soulaymani Bencheikh R. Safety monitoring of herb-drug interactions: A component of pharmacovigilance. Drug Saf. 2012; 35(10): 785-91. DOI: 10.1007/BF03261966
5. Arnott J, Hesselgreaves H, Nunn AJ, et al. What can we learn from parents about enhancing participation in pharmacovigilance? Br J Clin Pharmacol. 2013; 75(4): 1109-17. DOI: 10.1111/j.1365-2125.2012.04428.x
6. Gerritsen R, Faddegon H, Dijkers F, et al. Effectiveness of pharmacovigilance training of general practitioners: A retrospective cohort study in the Netherlands comparing two methods. Drug Saf. 2011; 34(9): 755-62. DOI: 10.2165/11591600-000000000-00000
7. Kshirsagar N, Ferner R, Figueroa BA, et al. Pharmacovigilance methods in public health programmes: The example of miltefosine and visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2011; 105(2): 61-7. DOI: 10.1016/j.trstmh.2010.11.002
8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA. 1998; 279(15): 1200-5. DOI: 10.1001/jama.279.15.1200
9. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 1993; 46(11): 1323-30. DOI: 10.1016/0895-4356(93)90101-6
10. Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: A systematic review. Drug Saf. 2008; 31(1): 21-37. DOI: 10.2165/00002018-200831010-00002
11. Macedo AF, Marques FB, Ribeiro CF, Texeira F. Causality assessment of adverse drug reactions: Comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol Drug Saf. 2005; 14(12): 885-90. DOI: 10.1002/pds.1119
12. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979; 242(7): 623-32. DOI: 10.1001/jama.1979.03300070033022
13. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2): 239-45. DOI: 10.1038/clpt.1981.154
14. Mashford ML. The Australian method of drug-event assessment. Special workshop – regulatory. Drug Inf J. 1984; 18(3-4): 271-3. DOI: 10.1177/009286158401800314
15. Hutchinson TA. Computerized Bayesian ADE assessment. Drug Inf J. 1991; 25: 235-41. DOI: 10.1177/009286159102500117
16. Hutchinson TA, Dawid AP, Spiegelhalter DJ, et al. Computerized aids for probabilistic assessment of drug safety: I. A spreadsheet program. Drug Inf J. 1991; 25: 29-39. DOI: 10.1177/009286159102500106
17. World Health Organization (WHO), Uppsala Monitoring Centre. The use of the WHO-UMC System for Standardized Case Causality. DOI: Not available (WHO publications generally do not have DOIs).
18. Harmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008; 64: 743-52. DOI: 10.1007/s00228-008-0475-9
19. Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol. 2007; 39: 124-8. DOI: 10.4103/0253-7613.33432
20. Coulter DM. The New Zealand intensive medicines monitoring programme in proactive safety surveillance. Pharmacoepidemiol Drug Saf 2000; 9: 273-80. DOI: 10.1002/(SICI)1099-1557(200007/08)9:4<273:: AID-PDS501>3.0.CO;2-8
21. Mackay FJ. Post-marketing studies: The work of the drug safety research unit. Drug Saf. 1998; 19: 343-53. DOI: 10.2165/00002018-199819050-00002
22. Folb PI, ten Ham M. Drug monitoring in developing countries: A drug regulator’s perspective. Drug Inf J 1995; 29: 303-5. DOI: 10.1177/009286159502900133 Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol. 1998; 45: 427-31. DOI: 10.1046/j.1365-2125.1998.00711.x
23. Moore N. The role of the clinical pharmacologist in the management of ADRs. Drug Saf. 2001; 24: 1-7. DOI: 10.2165/00002018-200124010-00001
24. Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of ADRs by nurses. Br J Clin Pharmacol. 1995; 40: 173-5. DOI: 10.1111/j.1365-2125.1995.tb04536.
25. Hornbuckle K, Wu HH, Fung MC. Evaluation of spontaneous adverse event reports by primary reporter: A 15-year review (1983 to 1997). Drug Inf J. 1999; 33: 1117-24. DOI: 10.1177/009286159903300418
26. Vorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: The nonpharmacologic basis of therapeutics. Ann Intern Med. 2000; 133: 128-35. DOI: 10.7326/0003-4819-133-2-200007180-00010
27. Ball LK, Evans G, Bostrom A. Risky business: Challenges in vaccine risk communication. Pediatrics. 1998; 101: 453-8. DOI: 10.1542/peds.101.3.453
28. Bapna JS, Tripathi CD, Tekur U. Drug utilization patterns in the third world. Pharmacoeconomics. 1996; 9: 286-94. DOI: 10.2165/00019053-199609040-00005
29. de Vries CS, Duggan CA, Tromp TF, de Jong-van den Berg LT. Changing prescribing in the light of tolerability concerns: How is this best achieved? Drug Saf. 1999; 21: 153-60. DOI: 10.2165/00002018-199921020-00006
30. Sleath B, Svarstad B, Roter D. Physician motivation for non-scientific drug prescribing. Soc Sci Med. 1997; 44: 541-8. DOI: 10.1016/S0277-9536(96)00177-6
31. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA. 2001; 285: 437-43. DOI: 10.1001/jama.285.4.437
32. Waller PC, Wood SM, Langman MJ, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. BMJ. 1992; 304: 1470-72. DOI: 10.1136/bmj.304.6836.1470
33. Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in hospitalized patients. JAMA. 1998; 279: 1200-1205. DOI: 10.1001/jama.279.15.1200
34. Bord CA, Rachi CL. Adverse Drug Reactions in United States Hospitals. Pharmacotherapy. 2006; 26(5): 601-08. DOI: 10.1592/phco.26.5.601
35. Arimone Y, Begnad B, Miremont G, et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol. 2005; 61: 169-173. DOI: 10.1007/s00228-004-0875-5
36. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of seven medical areas. JAMA. 2001; 285(4): 437-443. DOI: 10.1001/JAMA.285.4.437
37. Biswas P, Biswas AK. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol. 2007; 39: 124-128. DOI: 10.4103/0253-7613.33432
38. Moore N. The role of clinical pharmacologist in the management of ADRs. Drug Saf. 2001; 24(1): 1-7. DOI: 10.2165/00002018-200124010-00001
39. Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of ADRs by nurses. Br J Clin Pharmacol. 1995; 40: 173-175. DOI: 10.1111/j.1365-2125.1995.tb04536.x
40. Hornbuckle K, Wu HH, Fung MC. Evaluation of spontaneous adverse event reports by primary reporter: A 15-year review (1983-1997). Drug Inf J. 1999; 33: 1117-24. DOI: 10.1177/009286159903300418 (This is a duplicate of reference 30).
41. Egberts GPG, Smulderes M, De Koning FHP, et al. Can ADRs be detected earlier? A comparison of reports by patients and professionals. BMJ. 1996; 313: 530-531. DOI: 10.1136/bmj.313.7054.530